Stockscreener 앱 받기
1.66
18.57%
0.26
시간 외 거래:
1.63
-0.03
-1.81%
Protalix BioTherapeutics Inc. 주식(PLX)의 최신 뉴스
PLX: Self-Sustaining Rise to Lead in Renal Rare Disease - Yahoo Finance
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2024 Earnings Call Transcript - Insider Monkey
Protalix BioTherapeutics Inc. (PLX) Quarterly 10-Q Report - Quartzy
Protalix: Q3 Earnings Snapshot - New Haven Register
Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Protalix BioTherapeutics Reports Strong Q3 2024 Results - TipRanks
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results - citybiz
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 - The Malaysian Reserve
Protalix BioTherapeutics Sets Q3 2024 Earnings Call for November 14 | PLX Stock News - StockTitan
Accolade And 2 Other Penny Stocks To Watch On US Exchanges - Simply Wall St
Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes - openPR
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GuruFocus.com
Protalix BioTherapeutics Announces Repayment of Outstanding Seni - GuruFocus.com
PLXProtalix BioTherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 - PR Newswire
OTC Markets Hosts Virtual Investor Presentation with Dror Bashan, President & CEO of Protalix Biotherapeutics, and John Vandermosten, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024 - GlobeNewswire
Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes - Kilgore News Herald
Is Protalix BioTherapeutics Inc. (PLX) worth investing in despite its overvalued state? - US Post News
Protalix BioTherapeutics Inc. (PLX) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts? - Yahoo Finance UK
Protalix BioTherapeutics clears debt, secures operational runway - Investing.com
Protalix BioTherapeutics clears debt, secures operational runway By Investing.com - Investing.com Canada
Protalix says FDA okays drug-trial design - Reuters
10 Best Rated Penny Stocks To Buy According to Analysts - Insider Monkey
Protalix BioTherapeutics, Inc. Expected to Post FY2024 Earnings of $0.06 Per Share (NYSE:PLX) - MarketBeat
Fabry Disease Market to Sour at a CAGR of ~6% by 2032, estimates - openPR
Analyzing Protalix BioTherapeutics (NYSE:PLX) & Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World
Protalix BioTherapeutics, Inc. to Post FY2024 Earnings of $0.06 Per Share, Zacks Small Cap Forecasts (NYSE:PLX) - Defense World
PLX: A Focus on Renal Rare Disease - Yahoo Finance
Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022 - BioSpace
Protalix BioTherapeutics (NYSE:PLX) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS - Defense World
Protalix BioTherapeutics (NYSE:PLX) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021 - BioSpace
Protalix BioTherapeutics Inc (PLX) Q2 2024 Earnings Call Transcr - GuruFocus.com
Protalix BioTherapeutics Inc. (PLX) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Earnings call: Protalix reports progress on PRX-115 and stable finances - Investing.com Australia
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2024 Earnings Call Transcript - Insider Monkey
Financial Health Report: Protalix BioTherapeutics Inc. (PLX)’s Ratios Tell a Tale - The Dwinnex
Protalix: Q2 Earnings Snapshot - Darien Times
Protalix BioTherapeutics to Present at the 2024 BIO International Convention - Longview News-Journal
Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024 - Longview News-Journal
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
3.66%
1.11%
자본화:
|
볼륨(24시간):